FY2023 Q2 Financial Results Presentation
Executive Officer CFO
Richard P. Kincaid

Descriptions of future events, etc. in this document include Healios’assumptions, prospects, etc.
based on information which could be acquired at the time this document was presented. For this reason,
actual performance, development progress, etc. may differ from those described in this document
according to the outcome of R&D in the future, the actions of regulatory authorities, etc. in the future,
and uncertain/pending factors as of this point.
Also, this document contains information on regenerative medicine and medical equipment that are
currently under development or already on the market. Such information is not intended for promoting
advertising or providing medical advice.